Abstract: A novel compound is disclosed, said compound comprising hyaluronic acid, optionally cross-linked, or an oligomer, optionally cross-linked, dimer or monomer thereof, which is salified or at least partially salified with carnosine, wherein the carnosine is in the form of an L- or D-enantiomer or a racemate; a process for producing this compound, its cosmetic and therapeutic use as well as pharmaceutical and cosmetic compositions containing the same are also disclosed.
Abstract: The invention is based on a correlation observed between serotonin level and intestinal flora. The invention relates to a relative proportion of bifidobacteria in the intestine and in particular to a product increasing the ratio of bifidobacteria to Clostridia, to be used for raising the serotonin level. The invention also relates to a method for estimating a health risk associated with serotonin depletion by determining a relative proportion between bifidobacteria or Clostridia in the intestine or their ratio to one another. The invention further relates to a method for selecting a form of therapy for raising the serotonin level by determining a relative proportion between bifidobacteria or Clostridia in the intestine or their ratio to one another.
Abstract: The present invention is concerned with improved synergistic compositions effective in the treatment of diabetes and/or hyperglycemia. In particular, the present invention is concerned with synergistic compositions comprising inulin preparations having a defined degree of polymerisation (DP) of below about 25 and sulfonylureas and/or a sulfonamide and/or derivatives and/or metabolites thereof used in the treatment of Type-2 Diabetes Meliitus (T2DM). Said compositions are also used for preventing the development of or ameliorating, side-effects or conditions in a subject treated with sulfonylurea and/or a sulfonamide compounds (and/or derivatives and/or metabolites thereof, or combinations thereof), said side-effects including hypoglycemia, gastrointestinal disturbances, fatigue, weight gain, and satiety.
Abstract: The present invention provides a method for the treatment of eosinophilicesophagitis comprising administering non-digestible oligosaccharides.
Type:
Application
Filed:
October 6, 2011
Publication date:
October 9, 2014
Inventors:
Johan Garssen, Christophe Dupont, Catharina Theresia Knipping
Abstract: The invention relates to a sterile preparation which can be implanted on or in organic tissues, comprising: a natural or modified globin material which is insoluble at physiological pH and/or a material obtainable from globin which has been modified to be soluble at physiological pH, the said materials being biocompatible and biodegradable in the organism; an agent selected from natural or synthetic polymeric adhesive agents, polymeric tissue enhancement or filling agents, more particularly an agent based on crosslinked hyaluronic acid or on polylactic acid, and a polymeric wound cicatrization agent, specifically oxidized cellulose; with the provisos that, if the preparation comprises the said material obtainable from globin modified so as to be at least partly soluble, the said polymeric adhesive agent, if present, is not hyaluronic acid or carboxymethylcellulose and the said polymeric enhancement or filling agent, if present, is an agent based on crosslinked hyaluronic acid, and that, if the preparation com
Abstract: Described herein are polysaccharide gel formulations including at least one inhibitor of polysaccharide degradation and methods of making the same. The methods described herein involve the steps of providing at least one polysaccharide and incorporating at least one inhibitor of degradation into the polysaccharide. In some embodiments, the incorporating step comprises 1) mixing the at least one inhibitor with the at least one polysaccharide at a highly hydrated state thereby encapsulating the at least one inhibitor in a polysaccharide network, and 2) dehydrating the polysaccharide network thereby controlling release kinetics or final swell ratio. In another embodiment, the incorporating step comprises 1) encapsulating at least one inhibitor into a biocompatible or biodegradable vessel and 2) combining the polysaccharide and the vessel into a gel formulation. The polysaccharide gel formulations described herein can be used for a variety of cosmetic applications.
Type:
Grant
Filed:
March 27, 2013
Date of Patent:
October 7, 2014
Assignee:
Allergan, Inc.
Inventors:
Dimitrios Stroumpoulis, Christopher S. Mudd, Ahmet Tezel
Abstract: The present invention provides a method and composition for the treatment and/or prevention of infection, said method comprising orally administering a composition to a mammal, said composition comprising a galactose containing indigestible oligosaccharide and immunoglobulin from the milk or colostrum of hyperimmunized cows.
Type:
Application
Filed:
March 5, 2014
Publication date:
October 2, 2014
Applicant:
N.V. NUTRICIA
Inventors:
Günther BOEHM, Laura M'RABET, Bernd STAHL, Johan GARSSEN, Antony William SCAMMELL, Raymonde Peter PEETERS
Abstract: Implantable modular hydrogels to aid in salivary gland restoration and associated methods are provided. In one embodiment, the present disclosure provides for a hydrogel network comprising: a hyaluronic acid macromer crosslinked with a multiblock copolymer.
Type:
Application
Filed:
June 16, 2014
Publication date:
October 2, 2014
Inventors:
Robert L. Witt, Xinqiao Jia, Swati Pradham Bhatt, Mary C. Farach-Carson, Daniel A. Harrington
Abstract: The present invention provides a combination of rebamipide and a tear-retaining agent as a medicament for the treatment of anterior eye diseases.
Abstract: The present invention features, inter alia, biocompatible compositions that include a poloxamer and one or more additives such as hyaluronic acid, gelatin, fibronectin, or a peptide fragment of fibronectin. The compositions are useful in tissue repair or remodeling, including repair of an injured spinal disc, in drug delivery, in cell culture, and in inhibiting the formation of adhesions.
Type:
Application
Filed:
July 5, 2012
Publication date:
October 2, 2014
Applicant:
The Research Foundation of State University of New York
Abstract: Biomaterials obtainable by mixing the autocrosslinked derivative of hyaluronic acid (ACP) with the derivative (HBC) of hyaluronic acid crosslinked with 1,4-butanediol diglycidyl ether (BDDE) in the weight ratio of between 10:90 and 90:10 as novel fillers.
Abstract: Aspects of the invention include methods for enhancing blood coagulation in a subject. In practicing methods according to certain embodiments, an amount of a non-anticoagulant sulfated polysaccharide (NASP) in combination with a gastrointestinal epithelial barrier permeation enhancer is orally administered to a subject in a manner sufficient to enhance blood coagulation in the subject. Compositions and kits for practicing methods of the invention are also described.
Type:
Grant
Filed:
July 18, 2012
Date of Patent:
September 30, 2014
Assignees:
Baxter International Inc., Baxter Healthcare S.A.
Abstract: The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent cation salt such as magnesium chloride.
Type:
Grant
Filed:
May 13, 2013
Date of Patent:
September 30, 2014
Assignee:
Alcon Research, Ltd.
Inventors:
Howard Allen Ketelson, James W. Davis, David L. Meadows
Abstract: The present invention includes a composition and method of treatment having arabinogalactan and polyphenols from larch trees for the use in prophylactic treatment of upper respiratory tract infections. The invention also includes treatment using such composition.
Abstract: Disclosed are compositions comprising crosslinked hyaluronic acid gels, preferably vinyl sulfone cross-linked hyaluronic acid known as hylan B gel, for use in topical cosmetic and dermatological formulations. The hylan B gel in these formulations provides prolonged delivery of incorporated substances to the surface of the skin, to provide a hydrated film on the surface of the skin, and to provide a substantive and compatible film on the skin.
Type:
Application
Filed:
March 18, 2014
Publication date:
September 25, 2014
Applicant:
LUROMED LLC
Inventors:
Adelya K. Leshchiner, Nancy E. Larsen, Edward G. Parent
Abstract: Functionalized chondroitin sulfate, cross-linked polymer matrices comprising functionalized chondroitin sulfate, and methods of making and using the same are provided. Such polymer matrices may be used for tissue engineering, reconstructing cartilage, and the like. Kits are also provided for detection of cartilage degrading enzymes.
Type:
Application
Filed:
March 17, 2014
Publication date:
September 25, 2014
Applicants:
The Johns Hopkins University, The United States, as represented by the Secretary Department of Health & Human Services, University of Maryland, Baltimore
Inventors:
Jennifer H. Elisseeff, Rocky S. Tuan, Qiang Li, Dongan Wang, Ronald Paul Silverman
Abstract: The invention provides a pharmaceutical composition comprising a macromolecular drug and an oligoguluronate or oligogalacturonate, e.g., having a number average degree of polymerization in the range 5 to 18, a guluronate (or galacturonate) fraction (FG) of at least 0.80, a mannuronate fraction (FM) of no more than 0.20, and having at least 95% mole with a degree of polymerization less than 20. The composition may be used in a method of treatment which comprises administering the composition to a mucosal surface in a human or non-human vertebrate subject.
Type:
Grant
Filed:
April 11, 2008
Date of Patent:
September 23, 2014
Assignee:
Norwegian University of Science and Technology
Inventors:
Catherine Taylor, Kurt Ingar Draget, Olav Asmund Smidsrod
Abstract: A treatment for gray hair is described. The treatment can include a composition for treating gray hair with an active mixture including black trap molasses and vinegar. A standard ratio of vinegar to blackstrap molasses can be at least 1:10. The treatment can also include providing an ingestible hair treatment product including the active mixture and administering a quantity of the hair treatment product to deliver an effective amount of the active mixture.
Abstract: The use of pectins and/or polymers to prevent nicotine oxidation in tobacco containing products is disclosed. These polymers may be naturally occurring anionic polymers or synthetic polymers. These pectins and/or polymers prevent nicotine from oxidizing into cotinine, nicotine-cis-N-oxide, nicotine-trans-N-oxide, and/or nicotine-1,1-di-N-oxide. Molluscicides, algaecides, pesticides, and stabilized nicotine compositions comprising nicotine and pectin, anionic polymers, or combinations thereof are disclosed.
Type:
Application
Filed:
March 12, 2014
Publication date:
September 18, 2014
Applicant:
Altria Client Services Inc.
Inventors:
Munmaya K. Mishra, Jason Flora, Georgios D. Karles, Christophe Claude Galopin, Diane Gee, John B. Paine, III, Douglas Antonio Fernandez
Abstract: The present disclosure relates to hyaluronic acid derivatives, and in particular, derivatives in which the N-acetyl group of hyaluronic acid has been substituted, and methods and uses thereof.
Abstract: Uses of depolymerized hyaluronan (e.g., prepared by sonicating high molecular weight hyaluronan such as naturally-occurring hyaluronan) or anti-Hyal-2 antibody in cancer treatment. Also described herein are methods for preparing depolymerized and crosslinked hyaluronan by sonication and the hyaluronan composition thus obtained.
Abstract: Beta glucan and fulvic acid can be combined in a dietary supplement as a partial substitute or complete replacement for blue green algae and/or brown seaweed and its derivatives. Beta glucans are widely available as derivatives of Brewer's yeast and fulvic acid is widely available as well. These supplements are not subject to the vagaries of weather-influence growing seasons as is the case with blue green algae and brown seaweed. When combined, beta glucan and fulvic acid can provide a less costly dietary supplement than blue green algae and brown seaweed and its derivatives such as fucoidan.
Abstract: Provided herein are pre-formulations forming a biocompatible hydrogel polymer comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the biocompatible hydrogel polymer covers a wound in a mammal and adheres to the surrounding skin tissue. In other embodiments, the hydrogel polymer is delivered into a joint space to treat joint disease or navicular disease.
Type:
Application
Filed:
March 14, 2014
Publication date:
September 18, 2014
Applicant:
Medicus Biosciences LLC
Inventors:
Syed H. ASKARI, Yeon S. CHOI, Paul YuJen WAN
Abstract: Described herein are compounds and compositions for the amelioration of arthritis or joint injuries by inducing mesenchymal stem cells into chondrocytes.
Type:
Application
Filed:
March 13, 2014
Publication date:
September 18, 2014
Applicants:
The Scripps Research Institute, The California Institute for Biomedical Research
Inventors:
Peter G. SCHULTZ, Arnab K. CHATTERJEE, Shoutian ZHU, Joshua PAYETTE, Hongchul YOON, Baiyuan YANG
Abstract: A composition suitable for topical application, for example, is provided. In some examples, the composition can include particular cyclic oligosaccharides, a fragrance, and a volatile solvent. The compositions disclosed herein may provide a longer lasting fragrance.
Type:
Application
Filed:
March 14, 2014
Publication date:
September 18, 2014
Applicant:
The Procter & Gamble Company
Inventors:
Timothy Alan Scavone, Brian Francis GRAY, Peter Christopher ELLINGSON, Dean Larry DUVAL, Misael Omar AVILES, Victor Nicholas VEGA
Abstract: Compositions and methods relating to fucan agents useful for the treatment, prevention, inhibition, etc., of fibrous adhesions or other diseases.
Abstract: Compositions provided by contacting a biotin-containing component and an avidin-containing component are useful as drug delivery devices. Bioactive agents may be covalently bound to the biotin-containing component, the avidin-containing component, or both, mixed therewith, or combinations of the foregoing.
Type:
Grant
Filed:
November 18, 2011
Date of Patent:
September 16, 2014
Assignee:
Covidien LP
Inventors:
Timothy Sargeant, Joshua Stopek, Ahmad Robert Hadba
Abstract: The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to achieve hemostasis at an increased rate. More specifically the present invention relates to hemostatic compositions that achieve a hemostatic effect at a distance from the site of application of the composition, and a method for administering such a composition to effectively reduce localized vascular complications associated with treating a breach or puncture in a vein or artery and reduce the time to achieve hemostasis.
Type:
Grant
Filed:
March 25, 2011
Date of Patent:
September 16, 2014
Assignee:
Marine Polymer Technologies, Inc.
Inventors:
John N. Vournakis, Sergio Finkielsztein
Abstract: A method for the augmentation of immune function is described. The invention comprises a combination of ?-1,3 (4)-endoglucanohydrolase, ?-1,3 (4)-glucan, diatomaceous earth, mineral clay and glucomannan, which is fed to or consumed by mammalian or avian species in amounts sufficient to augment immune function. The invention described may be admixed with feeds or foods, incorporated into pelleted feeds or foods or administered orally to mammalian and avian species.
Abstract: A method of treating a patient inflicted with Reynaud's Disease including the step of injecting into the back of the patient's hand an effective amount of a hyaluronic product, thereby creating a glove-like insulation to decrease the blood vessel vasospasm.
Abstract: A pharmaceutical composition for inhibiting inflammation is provided. The pharmaceutical composition comprises (a) hyaluronic acid, (b) a vitamin and (c) a pharmaceutically acceptable carrier.
Abstract: Disclosed is a method for preparing polysaccharides of green tea, and more particularly to a method for preparing polysaccharides of green tea comprising the steps of: a) removing chlorophyll and a low molecular weight polyphenol from green tea powder using a solvent; b) hot-water extracting a water-soluble active ingredient from the green tea residue of step a); and c) separating the polysaccharides of green tea from the hot-water extract of step b) by ultrafiltration and ethanol precipitation. Also, the present invention relates to a cosmetic composition for skin whitening, moisturization and anti-wrinkle effects comprising the polysaccharides of green tea as an effective ingredient.
Type:
Grant
Filed:
May 6, 2009
Date of Patent:
September 16, 2014
Assignee:
Amorepacific Corporation
Inventors:
Sun Sang Kwon, Myeong Hun Yeom, Duck Hee Kim, Han Kon Kim, Nok Hyun Park, Soo Mi Ahn
Abstract: The present invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of ?-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The present invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedures that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2-6 and the temperature of 100-120° C., and pH is adjusted to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative degradation product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.
Abstract: Compositions and methods involving administration of agents useful for the treatment, prevention, inhibition, etc., of inflammatory disease or fibrous adhesions using low sulphate fucans and, if desired, one or more other anti-inflammatory disease or anti-fibrous adhesion agent.
Type:
Application
Filed:
April 15, 2013
Publication date:
September 11, 2014
Applicant:
Arc Medical Devices, Inc.
Inventors:
Johanne Cashman, Christopher Michael Kevin Springate, Charles Winternitz
Abstract: A wound dressing having anti-microbial activity comprises a first fibre capable of bonding with silver (1) cations. The wound dressing comprises a blend of the first fibre to which silver (1) cations are bonded and a second fibre which is substantially free from silver. The wound dressing comprises from 0.01 to 5.0 percent by weight of silver (1) cations, based on the weight of fibre.
Abstract: The embodiments herein provide a method for isolation and purification of a novel oligosaccharide molecule from the fruits of Rosa arvensis for the treatment of diabetes. The fruit is dried, powdered and subjected to deionized water. The deionized water solution is subjected to silica gel column and the filtrate is subjected to ethanol-water mixture. The filtrate is subjected to column chromatography. The purified extract is structurally and chemically analyzed to find that the molecule is oligosaccharide. The purified oligosaccharide is administered to diabetic patients for 21 days. After the administration of oligosaccharide for 21 days the pancreatic tissues are collected and the blood glucose level in fasting and non fasting states is measured to find that there is significant effect in the blood glucose levels and the pancreatic tissue/cell regeneration after administration of the isolated oligosaccharide. The toxicity tests reveal that the oligosaccharide is non-toxic in nature.
Abstract: While tumor hypoxia is recognized as a key barrier to effective chemo and radiation therapy of solid tumor malignancies, and an important biological mediator of more aggressive tumor phenotype and behavior for over 50 years, prior attempts to improve tumor oxygenation have relied on increasing the total amount of oxygen bound to each molecule of natural hemoglobin (e.g. through hyperbaric oxygen treatments), increasing the ease of release of oxygen from hemoglobin (through the introduction of exogenous allosteric small molecules), or increasing the total amount of oxygen in the body by injecting perfluorocarbon emulsions, or polymerized or pegylated compositions of natural human or bovine hemoglobin. The embodiments provide a novel approach of introducing into the vascular system agents that possess inherently higher-affinities for molecular oxygen that that of natural human hemoglobin, and coupling these agents with inert carriers that shield them from unwanted biological interactions within the body.
Abstract: Disclosed are nutritional compositions including human milk oligosaccharides in combination with long chain polyunsaturated fatty acids and/or carotenoids that can be administered to preterm infants, term infants, toddlers, and children for reducing inflammation and the incidence of inflammatory diseases.
Type:
Application
Filed:
March 4, 2014
Publication date:
September 11, 2014
Applicant:
Abbott Laboratories
Inventors:
RACHAEL BUCK, GERALYN O. DUSKA-MCEWEN, JOSEPH P. SCHALLER
Abstract: A method comprising administering an oligosaccharide composition to an organism having a gastrointestinal system to affect the production of GHG produced by the organism allowing for a reduction of the GHG produced by the organism while optimizing the health, feed intake, and protein synthesis of the organism so that management of the organism may realize the synergistic effects of maximizing both typical organism commodity-type concerns (e.g., size and production metrics) and atypical organism commodity-type concerns (e.g., carbon credit trading/monetization). A gas-reducing composition comprising soluble extractable material from a lignocellulosic source.
Type:
Grant
Filed:
August 26, 2010
Date of Patent:
September 9, 2014
Assignee:
Georgia-Pacific Wood Products LLC
Inventors:
Matthew W. Lowe, Anne Chace Hopkins, Thomas A. Lehtinen
Abstract: The present invention relates to a pharmaceutical composition for relieving pain in a joint disease, including a hyaluronic acid and a pharmaceutically acceptable carrier, in which the hyaluronic acid is cross-linked by cyclizing a double bond in the moiety of a cinnamic acid in a partially amidated hyaluronic acid represented by Formula (1): [Ar—CH?CH—COO—(CH2)n—NH-]m-HA, to form a cycloubutane ring, in which Ar represents an optionally substituted phenyl group, n represents an integer of 2 or 3, HA represents a carboxy residue of the hyaluronic acid, and m represents an amidation ratio of the hyaluronic acid to the total carboxyl group and is in the range of 3 to 50% relative to the total carboxyl group.
Type:
Grant
Filed:
August 13, 2010
Date of Patent:
September 9, 2014
Assignee:
Seikagaku Corporation
Inventors:
Hiroyuki Hosokawa, Sooyeol Lim, Junko Oda
Abstract: A nanoparticle of glucidamin derived from organism for treating tumor and preparation method thereof, wherein the viscosity-average molecular weight of glucidamin is in the range of 1×103-9×105, and the amount of free amino groups in the glucidamin is in the range of 50%-100% based on the total amino groups. The preparation method of the nanoparticle comprises steps listed below: (1) adding the glucidamin possessing one or more molecular weight into thin acid solution at 20-60° C. to form saccharan solution, wherein the content of saccharan in solution is in the range of 0.1%-5% by weight; (2) adjusting the pH of the solution to 6-9 in order to form emulsion of microparticle; (3) separating the microparticle from the emulsion, dried at low temperature to obtain the nanoparticle of glucidamin for treating tumor. The nano-class glucidamin can enhance their activity against tumor.
Abstract: Methods and compositions of the invention relate to the treatment of diabetic nephropathy and associated disorders. In particular, the methods and compositions use a pharmaceutical-grade galactose-pronged carbohydrate or pharmaceutical compositions thereof alone or in combination with other therapeutic agents.
Abstract: The present invention is a natural, cell-free tissue replacement that does not require difficult or extensive preparation made by washing tissue replacement in a solution including one or more sulfobetaines and an anionic surface-active detergent and washing the tissue replacement in serial solutions of the buffered salt to remove excess detergent. The natural, cell-free tissue replacement may be a nerve graft that supports axonal regeneration, guides the axons toward the distal nerve end and/or is immunologically tolerated. Other forms of the invention are a composition and kit prepared by the method of making a native, cell-free tissue replacement. The present invention may be modified for use in diagnostic, therapeutic, and prophylactic applications.
Type:
Application
Filed:
May 9, 2014
Publication date:
September 4, 2014
Applicant:
Board of Regents, The University of Texas System
Abstract: The novel biomaterial fillers containing cross-linked sodium alginate and the method for manufacturing same are used in the medical field and are intended for filling tissue lesions having a layered structure of varying compositions, such as cartilage, skin or the epithelium. These novel biomaterials have the special feature of being multiphasic, composite and functionalized, for medical use and, in particular, for treating tissue lesions having a layered structure of varying compositions. The biomaterials are particularly suitable for treating focal lesions of the articular cartilage.
Type:
Application
Filed:
April 24, 2012
Publication date:
September 4, 2014
Applicants:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIQUE, UNIVERSITE DE LORRAINE
Inventors:
Laurent Jacques Grossin, Jean-Claude Voegel, Pierre Gilbert Schaaf, Pierre Gillet, Christel Odette Henrionnet, Patrick Netter
Abstract: A topical applicator composition and process are described that decorporate radionuclides from radiologically-contaminated dermal surfaces and that further promote healing. The topical applicator includes a decorporation agent mixed with a plasticizing agent that forms a covering when applied to the dermal surface that decorporates radionuclides and minimizes their systemic migration. The topical applicator formulations can be delivered in conjunction with bandages and other application dressings.
Type:
Application
Filed:
June 30, 2011
Publication date:
September 4, 2014
Applicant:
BATTELLE MEMORIAL INSTITUTE
Inventors:
Tatiana G. Levitskaia, Karla D. Thrall, James M. Peterson, Glen E. Fryxell, Charles A. Timchalk, Barbara J. Tarasevich
Abstract: The invention concerns a complex based on an organic silicon derivative. The invention is characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight comprised between 150 and 750 kDa, said derivative being of general formula (I): RxSi(OH)4-x, (I) wherein: R is a (C1-C4)alkyl, and x=1 or 2. The invention also concerns the use of such a complex in the prevention or the repair of cutaneous damages.
Abstract: Disclosed herein are cohesive soft tissue fillers, for example, dermal and subdermal fillers, based on hyaluronic acids and pharmaceutically acceptable salts thereof. In one aspect, hyaluronic acid-based compositions described herein include a therapeutically effective amount of at least one anesthetic agent, for example, lidocaine. The present hyaluronic acid-based compositions including lidocaine have an enhanced stability and cohesivity, relative to conventional compositions including lidocaine, for example when subjected to sterilization techniques or when stored for long periods of time. Methods and processes of preparing such hyaluronic acid-based compositions are also provided.
Abstract: The invention provides compositions comprising lipid-conjugated forms of capsular polysaccharide A (PSA) from B. fragilis (referred to herein as PSA-LT), methods of isolating such forms and of making such compositions and methods for their use.
Type:
Application
Filed:
July 12, 2012
Publication date:
August 28, 2014
Applicant:
The Brigham and Women's Hospital, Inc,
Inventors:
Dennis L. Kasper, Deniz Erturk-Hasdemir, Barbara Reinap